Faculty – The BD&L Summit for Life Sciences

Brian Axe
Due Diligence Leader, ELANCO

view speaker profile

Brian Axe is the Due Diligence Advisor for Elanco Business Development.  Brian heads the group for scientific and technical due diligence evaluations associated with in-licensing, out-licensing, merger and acquisitions, and alternative deal structures.  Brian is also engaged in the due diligence evaluation and oversight associated with Elanco’s internal pipeline.

A biochemist by training, Brian began his career in the medical device industry in 1998 and subsequently joined the pharmaceutical industry in 2002.  In late 2009, Brian joined Lilly’s Global External R&D – Due Diligence group gaining extensive experience leading a variety of due diligence projects across all phases of development and therapeutic areas, in all geographies.  Brian has focused extensively in the emerging markets, with diverse deal structures, and has lead partnering and portfolio oversight associated with Lilly’s out-licensing efforts, academic hubs and VC funding collaborations.  Through Brian’s out-license experience, Brian also has a proficiency in the preparation and oversight of external data rooms.

Matthew Batters, J.D.
Executive Director, Transactions, Alliance Management, Business Development and Corporate Counsel, ARVINAS

Lisa Beck
Vice President, Business Development and Alliance Management, BRII BIOSCIENCES

Zubin Bhagwagar, M.D., Ph.D.
Global Program Lead, RALLYBIO

Janice Bourque
Managing Director, Life Sciences, HERCULES CAPITAL

Isaac J. Bright
Chief Executive Officer, RUBRYC THERAPEUTICS

Brian Bronk, Ph.D.
Head of Business Development, Rare Diseases & Rare Blood Disorders, SANOFI

view speaker profile

Brian joined the Sanofi Business Development team in 2017 as head of External Innovation, Rare Diseases. In this role, he and his teams have worked with senior leadership to define an overall portfolio strategy, with accountability for identifying and securing external opportunities that meet the needs of the R&D portfolio. Previously, Brian was a member of the Sunrise team, where his efforts focused on building and maintaining a portfolio of investments, including MyoKardia, Portal, Warp Drive Bio, DiCE and Thermalin.

Prior to joining Sanofi in 2014, Brian was Vice President of Research and Development at Satori Pharmaceuticals, where he was a member of the Executive Leadership team and led chemical sciences and drug metabolism. He also advised several venture capital and life science groups; his efforts contributed to a number of successful financing rounds, as well as advancing R&D portfolios through key milestones Brian started his professional career with Pfizer (1994-2008), rising to the level of Senior Director. During this tenure, his responsibilities included shaping R&D strategy across multiple platforms and therapeutic areas, building and leading multi-disciplinary research and development teams and delivering clinical candidates in psychiatry, neurology, infectious diseases and metabolic disorders. By focusing on innovation and collaboration, Brian and his teams have been involved in the discovery of more than twenty development candidates, including the launched products Draxxin™, Convenia™, Cerina™ and Slentrol™.

Brian earned his bachelor’s degree from Colgate University in 1989. Following a year as a Fulbright Fellow in Dortmund, Germany, he initiated his doctoral work at the Massachusetts Institute of Technology, receiving his doctorate in chemistry in 1994.

Sascha Bucher
Head of Global Transactions and Head Basel Office, ROIVANT SCIENCES

view speaker profile

Sascha Bucher is Roivant’s Head of the Basel Office and Head of Global Transactions. Prior to joining Roivant, Sascha worked for Roche in numerous Business and Corporate Development functions including as Deputy Head of Global M&A where he was involved in 100+ transactions and negotiated and closed over 35 international deals. Prior to Roche, Sascha was a banker at UBS. He holds an MBA in Finance and Economics from the University of Basel, and is both a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager.

Kleem Chaudhary
Head BD&L MS, AD, OPN, Platforms, BIOGEN

view speaker profile

Dr. Kleem Chaudhary is Head of Business Development & Licensing for MS, AD, OPN, and Platforms at Biogen in Cambridge, MA. He has over 15 years of experience within the biotech and large pharma industry with broad experience across business development and licensing as well as in strategy and basic drug discovery. Prior to joining Biogen, Dr. Chaudhary was in business development at Takeda focused on gastroenterology and oncology transactions. He began his business development career and spent almost a decade at Novartis, where he was a transactions leader and led business development activities across multiple therapeutic areas. Prior to Novartis, he worked as a medicinal chemistry lab head at Gilead Sciences. Dr. Chaudhary holds a Ph.D. in chemistry from the University of North Carolina at Chapel Hill and a B.Sc. in chemistry from the University of Winnipeg.

Philip Datlow
Director and Senior Counsel, Intellectual Property, BOEHRINGER INGELHEIM

Behrad Derakhshan, Ph.D.
Vice President, Head of Business Development, THERACON

Niels P. Emmerich
Vice President, Global Head Search and Evaluation, ABBVIE

view speaker profile

After joining in 2011 Niels has held several positions at AbbVie, including Global Commercial Leader for a late-stage oncology program, Director and Head of Commercial Business Development for Oncology, Senior Director and Head of Search and Evaluation, Oncology, and most recently Vice President and Global Head of Search and Evaluation. Transactions that Niels was involved in include acquisitions (Pharmacyclics, Stemcentrx), R&D collaborations and license agreements (Argen-X, CALIBR, CytomX, Dong-A-ST, Harpoon, M2Gen, MD Anderson PureMHC, Turnstone, X-Chem) and venture investments. Prior to joining AbbVie Niels was CEO of BioPheresis, co-founder and COO of immatics, and working for McKinsey & Company. Niels attended University of Tuebingen and received a Master’s in Biology and a Ph.D. in Immunology.

John Fair
Chief Business Officer, DARÉ BIOSCIENCE

view speaker profile

Mr. John Fair is Chief Business Officer for Dare Bioscience and is responsible for licensing, acquisitions, strategic partnering and corporate strategy. In this role, Mr. Fair has been instrumental in building Dare’s pipeline from one asset to seven novel product candidates including a novel drug deliver platform technology. Prior to joining Dare Bioscience, Mr. Fair was President and Chief Operating Officer for Evofem, a privately held specialty healthcare company developing products for women’s health, microbiome and infectious disease. In that role, Mr. Fair was responsible for commercial strategy, operations and product development. He successfully initiated several new programs targeting bacterial and virologic diseases and microbiome disorders. Previously, Mr. Fair served in a number of executive level roles for specialty healthcare and private equity backed healthcare service businesses and was instrumental in building companies and capabilities that led to successful M&A exits. Mr. Fair has broad therapeutic experience that includes oncology, hematology, virology and women’s health. Mr. Fair began his career as a portfolio strategy and insights consultant and supported numerous brands and franchises in the pharmaceutical, OTC and consumer healthcare markets. Mr. Fair received his B.A. from Rider University and his M.S. from The University of Pennsylvania, Perelman School of Medicine. He has also completed executive education in corporate strategy, mergers and acquisitions at Stanford University Graduate School of Business and drug development and commercialization at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.

Teresa Faria, Ph.D.
Senior Director, Alliance Management, External Scientific Affairs, DAIICHI SANKYO

view speaker profile

Teresa Faria leads Global Development Alliance Management at Daiichi Sankyo. She also is responsible for Integration/Transition planning for in-licensed assets. Prior to joining DSI, Teresa was Director, Alliance Management, responsible for Research and early Development Alliances across a variety of Therapeutic Areas at Bristol-Myers Squibb. Teresa completed postdoctoral training at NIH and at Weill-Cornell Medical School. Teresa earned a PhD in Developmental Biology from the University of Kansas School of Medicine.

Steven Gurney
Principal Associate and Patent Attorney, MARKS & CLERK

view speaker profile

Steven Gurney — Principal Associate. Chartered (UK), European and Registered (AU, NZ) Patent Attorney.

Steven specialises in small molecule pharmaceutical patents with experience gained working both in-house and in private practice. He takes a collaborative approach, understanding his clients’ commercial drivers to deliver relevant, pragmatic and actionable advice. Steven works with pharmaceutical companies, universities and start-ups in the fields of small molecule medicines, general chemistry and medical devices. Steven provides strategic advice to his clients, advising on freedom to operate (FTO), due diligence, advice, opposition, and litigation. He is also experienced in drafting pharmaceutical patent applications and also manages the resultant patent portfolios including global prosecution.

Joe Herold
Chief Legal Officer and Chief Compliance Officer, DRI CAPITAL

Timothy Herpin
Chief Business Officer, CARIBOU BIOSCIENCES

view speaker profile

Timothy Herpin Ph.D., is CBO of Caribou Biosciences where he leads the company’s efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities. Prior to Caribou, Tim was Vice President, Head of Transactions at AstraZeneca and led a group of business development professionals involved in all aspects of transactions negotiation and execution. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for Neuroscience and subsequently for Oncology. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

Ruby Holder
Vice President, Investments, ROIVANT SCIENCES

view speaker profile

Ms. Holder is a Vice President of Investments for Roivant Sciences, Inc., a multi-national biopharmaceutical company. She is based in New York City. Prior to joining Roivant Sciences in 2016, she spent over 15 years as a healthcare investor. Ms. Holder was a healthcare Portfolio Manager for Greywall Asset Management and Straus Asset Management.

Before starting her career in finance, Ms. Holder spent 10 years working in industry. Her experience spanned health-care consulting as well as operational roles at large academic medical centers. Ms. Holder holds a Bachelor of Science degree (Biomedical Engineering) and a Master of Business Administration degree, both from Duke University. She currently serves on the Duke University School of Nursing Board of Advisors and is member of the Executive Committee.

Rick Hoyt
Vice President, Business Development and Licensing, MALLINCKRODT

view speaker profile

Prior to his current position as Mallinckrodt’s Vice President of Business Development and Licensing, Rick served Covidien, the former parent of Mallinckrodt Pharmaceuticals, in a variety of roles including Vice President of Assets and Portfolio Management, Vice President Business Development, Vice President and General Manager New Products and Technology and General Manager Operations. Rick started his career with Mallinckrodt as a chemist and in addition to the roles above has held a number of business management, quality, and operational positions. He led the spin of Mallinckrodt from Covidien and number of transactions since the spin including the acquisition of Cadence Pharmaceuticals, Questcor, and Ikaria. Prior to the spinoff of Mallinckrodt, he led the divestiture of Covidien’s specialty laboratory business (Mallinckrodt Baker) to New Mountain Capital.

Will James
Partner and Solicitor, MARKS & CLERK

view speaker profile

Will James is an intellectual property lawyer who advises clients on IP issues in a wide range of technical industries. His particular expertise is in advising on patent issues (including SPCs) in the biotech and pharmaceutical sectors, where he has advised on IP issues in a number of core technologies including antibody engineering systems (transgenic mice and antibody phage display), DNA arrays and sequencing technology, reverse genetics, stem cells and erythropoietin litigation. Will advises clients on commercial issues and IP licensing as well as due diligence, freedom to operate and IP strategy. He has been involved in a number of multi-jurisdictional commercial matters including complex worldwide securitisations of future patent royalty streams.

Will is listed as an ‘IP Star’ by Managing Intellectual Property and in Legal 500. He is also listed as an expert by Who’s Who Legal for patents and for life sciences.

Will was also included in the LMG Life Sciences Guide as a ‘Life Sciences Star’.

Chinmay Kanuga
Director, Scientific Assessments and Due Diligences, ALLERGAN

Adam Kundzewicz, Ph.D.
Head of Strategic Market Access Initiatives, BOEHRINGER INGELHEIM

view speaker profile

Adam is currently working within the Corporate Market Access, Customer Value Group at Boehringer Ingelheim in Ingelheim, Germany, as a Head of Strategic Market Access Initiatives. In his role, he is responsible for orchestrating and piloting the strategic customer collaboration initiatives and helping to optimise market access excellence standards and processes within the Organisation.

Adam has started his career with Boehringer Ingelheim in 2012 as a Senior Global Payer Strategy Manager working in oncology and HCV in Ingelheim, Germany. He was managing global pricing and market access strategies for the HCV and oncology portfolio and driving the development of innovative market access approaches and payment schemes. He then moved to the UK and Ireland Organisation in 2015 to Head the Pricing and Contracting Team, working across the whole Boehringer Ingelheim prescription medicines portfolio.

Prior to joining Boehringer Ingelheim, Adam worked as a life sciences strategy consultant for IMS Consulting, Truven Analytics and Simon-Kucher & Partners in Belgium, France, Germany, Poland, Romania and The United States. He also worked as a research assistant at Jules Gonin Eye Hospital in Lausanne, Switzerland and as a Junior Project Leader at AnalyCen in Poland and Sweden.

Adam holds an M.Sc. in Molecular Biology and Biotechnology from University of Warsaw, Poland, and a Ph.D. in Neurosciences from University of Geneva, University of Lausanne and EPFL, Switzerland. He has published several articles in international peer-reviewed journals and lectured at international conferences on developmental neuroscience and retinal degeneration.

Tom Lynch
Chief Administrative Officer, General Counsel and Secretary, OREXIGEN

Bethany Mancilla
Chief Business Officer and Senior Vice President, CUE BIOPHARMA

view speaker profile

Bethany Mancilla has more than 20 years of strategic biopharmaceutical business development experience. Bethany is currently the Senior Vice President and Chief Business Officer for Cue Biopharma where she recently spearheaded a multi-target collaboration with LG Chem Life Sciences. Prior to joining Cue Biopharma, she served as Vice President, Business Development at Amgen. While at Amgen, Ms. Mancilla established key partnerships with Novartis to advance medicines for migraines and Alzheimer’s disease, Merck to expand immuno-oncology therapeutics and Servier to impact cardiovascular disease. Before joining Amgen, Ms. Mancilla was Vice President, Business Development at Micromet a company focused on proprietary bi-specific T-cell engaging therapeutics for oncology.

Mike Myers
Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY

view speaker profile

Dr. Mike Myers has spent 30 years in the industry contributing to the discovery and development of new drugs. He has led drug discovery teams in the pursuit of innovative treatments for cancer, CNS, Infectious and Cardiovascular diseases. Across these areas of significant need, Dr. Myers has contributed as an inventor on more than 35 patents. Dr. Myers has also led efforts in evaluating new lead generation technologies, predictive ADMET and computational chemistry approaches and led a significant effort at Lilly to optimize Lead generation processes in early drug discovery. More than 12 years ago, Dr. Myers moved from his Drug Discovery role to Sr. Director of Project Management and he was engaged in project and portfolio management. Currently, Mike’s main responsibilities within the External Innovation team at Eli Lilly & Company includes leading scientific Due Diligence activities in support of in-license/acquisition, out-license and strategic partnering activities.

Carolyn Ng

George Ng

view speaker profile

George Ng is a Co-Founder and current President, Business, of Scilex Pharmaceuticals, Inc. Mr. Ng has also held various other senior management positions, including Chief Administrative Officer, Corporate Secretary, Chief Legal Officer, General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded, global biotechnology and pharmaceutical companies, including Sorrento Therapeutics (NASDAQ: SRNE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). In these roles, Mr. Ng helped lead the commercialization efforts and launches of multiple pharmaceutical drug products. Previously, in private practice, Mr. Ng was a partner in two AMLAW 200 law firms, where he had leadership roles, including establishing the life sciences practice group for one firm and heading it as the national co-chair.

Mr. Ng was also a past President-Elect of the Pan Asian Lawyers of San Diego (PALSD) and was previously appointed to the Leadership Development Committee of the Wake County Bar Association in North Carolina. In addition, he is a frequent speaker and noted authority on legal, compliance and business issues in the life sciences, with past speaking engagements at the 2011 BIO International Convention and various pharmaceutical, legal and compliance congresses and conferences. Among his multiple awards and commendations, Mr. Ng is a recipient of the 2015 Outstanding 50 Asian Americans in Business Award, past recipient of M&A Advisor’s Top 40 Under 40 Award (in 2012) and nominee for the Orange County Business Journal’s Inaugural General Counsel Awards (in 2010); and, in 2010, MDB Capital recognized Mr. Ng (and the company where he led the intellectual property efforts) for its Best and Brightest Award and as an Astrum Award nominee for a pharmaceutical patent portfolio that he managed and developed. Mr. Ng earned a Juris Doctor (J.D.) degree in law from the University of Notre Dame School of Law and a Bachelor of Arts and Sciences (B.A.S.) dual degree in Biochemistry & Economics from the University of California, Davis.

Tara Nickerson
Chief Business Officer, THIRD ROCK VENTURES

Mark E. Nuttall
Chief Business Officer, KYMERA THERAPEUTICS

view speaker profile

Mark Nuttall is Chief Business Officer at Kymera Therapeutics LLC, a biotechnology company pioneering targeted-protein degradation as a transformative new approach to creating breakthrough medicines for patients. Dr. Nuttall joined Kymera from Sanofi Genzyme where he led business development and licensing for Immunology and Inflammation and Neuroscience. Dr. Nuttall has more than 25 years of experience in the biopharmaceutical industry. Prior to Sanofi Genzyme, Nuttall was previously with Johnson & Johnson Innovation leading global strategy for Neuroscience business development and was responsible for leading a team that transformed J&J’s CNS portfolio into one of the strongest in the industry. Mark holds a Ph.D from the University of Aberdeen and has published over 40 full scientific articles.

William Pedranti

view speaker profile

William Pedranti is a Co-Founder and current President, Operations, of Scilex Pharmaceuticals, Inc. Mr. Pedranti has more than 15 years of experience serving as senior counsel and as a senior executive at leading biotech and pharmaceutical companies, including the past six years at Scilex. Previously, Mr. Pedranti was Vice President and General Counsel for Spectrum Pharmaceuticals (NASDAQ: SPPI) and helped oversee its transformation from an early-stage clinical company to a successful commercial company. During Mr. Pedranti’s career, he has facilitated equity financing transactions that have raised more than $350 million and participated in the acquisition of over a dozen products. Additionally, Mr. Pedranti has been responsible for out-licensing transactions that generated more than $65 million in upfront fees. He has also supported the commercial launch of multiple drug products. Previously, in private practice, Mr. Pedranti was a partner in two AMLAW 200 law firms, where he was the national co-chair of the life sciences practice group for one firm. Mr. Pedranti started his legal career as an attorney with the international law firm Latham & Watkins LLP.

Mr. Pedranti is also a co-founder of several companies and serves as a member of the Board of Directors of IACTA Pharmaceuticals, an eyecare focused company, and Just C, the marketer of ARYA (aryaforlife.com), a consumer health drink. In addition, he is a speaker on regulatory, legal, compliance and business issues in the life science industry, and an annual guest lecturer with the University of Southern California Regulatory Science Program.

Mr. Pedranti received his Bachelor of Science (B.S.) in Business from the University of Southern California and his Juris Doctor (J.D.) from Georgetown University Law Center.

Martin Picard, Ph.D.
Vice President, Global Head Search, Evaluation and Due Diligence, MERCK KGAA

view speaker profile

Martin Picard, Ph.D., Vice President, Global Head Search, Evaluation & Due Diligence, has about 20 years’ experience as drug development expert and leader of global development programs for NCEs and NBEs across all phases and several therapeutic areas in 3 pharmaceutical companies. Since 2015 he has established an integrated Search, Evaluation and Due Diligence Unit within Merck KGaA, Darmstadt, Germany, which covers all R&D related aspects for inbound and outbound partnering from discovery to approval and across therapeutic areas. His academic background is Life Science, and he obtained his Ph.D. at the German Cancer Research Center (DKFZ) and the Center for Molecular Biology (ZMBH) in Heidelberg, Germany.

Joel Sangerman
Chief Commercial Officer, CLICK THERAPEUTICS

view speaker profile

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world. For over 25 years Joel has advanced new health technologies in the pharmaceutical industry. He is a graduate of DePaul University and a fellow of the Advisory Board Company.

Marc Schwabish
Senior Vice President, Business Development and U.S. Operations, FUSION PHARMACEUTICALS

Peter Seufer-Wasserthal
Chief Business Officer, ORIGENIS

view speaker profile

Dr. Peter Seufer-Wasserthal is Chief Business Officer at Origenis GmbH, a privately-held German biopharmaceutical company developing brain-penetrating highly selective small molecule medicines for a variety of neurodegenerative and neuroinflammatory diseases. Before joining Origenis, Dr. Seufer-Wasserthal held business development positions with growing responsibilities at Intrexon Corporation, Codexis Pharmaceuticals, and Morphochem in Munich. Dr. Seufer-Wasserthal started his industrial career with Chemie Linz AG as process chemist before moving into a position as New Business Development Manager. He received his Ph.D. from the Technical University of Graz.

Felice Shieh
Senior Director, External Science and Innovation, PFIZER

Kristen B. Slaoui
Vice President, Head of Business Development, North America, Corporate Strategy and Development, GSK

Chris Slavinsky
Assistant General Counsel, PFIZER

Jackie Spencer
Managing Director, Life Sciences and Healthcare, SILICON VALLEY BANK

view speaker profile

Jackie Spencer is a director at Silicon Valley Bank in San Francisco. Serving the Bay Area’s thriving biotech sector, Jackie provides banking services and debt-financing solutions to life science companies at all phases, from early-stage venture-backed enterprises to late-stage public companies. Her expertise also includes calling on the networks she’s built in her 10-plus years at SVB to make pivotal connections for her clients. Jackie takes a long view of her profession: She thrives on helping visionary companies flourish, increasing their chances of getting crucial therapeutics in the hands of doctors who can make all the difference in the lives of their patients. Jackie joined SVB in 2007, working in the bank’s technology practice area first as an associate and later as a vice president. For seven-plus years, she served enterprise and consumer application companies in the Bay Area, providing resources and tools to help these entrepreneurs scale their businesses. She received her bachelor’s degree from Saint Mary’s College of California in Moraga, California.

Peter Trybus
Senior Corporate Counsel, Healthcare Law, Managed Care Practice Group, GENENTECH

view speaker profile

Peter Trybus is Senior Corporate Counsel at Genentech’s Healthcare Law Group. As a member of the Managed Care Practice, Peter enjoys being able to make a difference for patients in working with business partners on getting the right medicine to the right patients at the right time in the right way, advising on strategic contracting matters, solutions to provide access to medicines, building strong compliance, pricing and reimbursement matters.

Peter has 15+ years background in transactions and corporate law. In 2009, he joined the Roche Group in Switzerland and worked in different legal roles on M&A transactions, finance, corporate structure and regional matters. Peter joined Genentech’s Transactional Law Group in South San Francisco in 2016, working closely with business development and scientists on licensing and collaboration transactions. In 2018, Peter moved from working on international deals to advising on US healthcare law matters, where he provides strategic advice to various functions in the commercial organization.

Michah Zajic
Vice President, Corporate Development, MEIRAGTX